Dry Age-related Macular DegenerationNCT04349254
Observational Study of Vision Improvement in Late Stage Dry AMD Patients
An observational study of Dry Age-related Macular Degeneration, run by Optimal Acuity Corporation at 1 site in Canada.
Trial summary
The purpose of this study is to assess the vision improvement achieved by patients with late stage dry age-related macular degeneration who received corneal treatments by a low vision aid device. Read more about this study
- Who is it for?
- Ages 50 to 100 yearsHealthy volunteers can take part
- Conditions the study is for
- Dry Age-related Macular Degeneration
- What is being tested?
- Corneal treatment by a low vision aid device
- Type of treatment
- Medical device
- How many people
- 17 participants
- Where
- 1 siteCanada
- Study dates
- 14 Aug 2020to 31 Dec 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 100 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients with vision impairment due to late stage dry age-related macular degeneration.
Who may be able to join
- - Male or female
- - Any race
- - Patient is at least 50 years old
- - Patient has diagnosed late stage dry age-related macular degeneration in one or both eyes.
- - Treated eyes were pseudophakic at the time of treatment.
- - Patient had moderate to severe baseline vision impairment with best spectacle-corrected distance visual acuity (CDVA) of 20/63 or worse (decimal = 0.317 or less; logMAR greater than or equal to 0.50) in the treated eye(s).
- - Patient CDVA records are available at baseline and at 12 month post-treatment.
Who cannot join
- - Corneal disease or disorder in either eye.
- - Increased intraocular pressure (above 20 mm Hg), glaucoma or history of glaucoma.
- - Presence or history of any other condition or finding that, in the opinion of the investigator, makes the patient unsuitable for retrospective observational study.
- -
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Observational Study of Vision Improvement in Late Stage Dry AMD Patients by a Low Vision Aid Device
The purpose of this study is to assess the vision improvement achieved by patients with late stage dry age-related macular degeneration who received corneal treatments by a low vision aid device.
Read the detailed description
The purpose of this study is to assess the vision improvement achieved by patients with late stage dry age-related macular degeneration who received corneal treatments by a low vision aid device. Patient records for patients with at least 12 months follow-up will be analyzed to determine measures of vision improvement including best spectacle-corrected distance and near visual acuity. Analyses will include descriptive statistics and correlation between outcomes and baseline characteristics.
- Conditions
- Dry Age-related Macular Degeneration
- Being tested
- Corneal treatment by a low vision aid device
- Keywords
- Dry AMD
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Corneal treatment by a low vision aid deviceDevice
Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The change of modulus produces a change of corneal stiffness and shape that modifies the distribution of light onto the retina. Light rays are redirected from dysfunctional areas of the retina that have been damaged by age-related macular degeneration (AMD) to functional areas of the retina, thereby improving patient vision.
What is being measured
The primary outcome is the main question the study is designed to answer.
CDVA
Best spectacle-corrected distance visual acuity (CDVA)
Measured: 12 months
Secondary outcomes (1)
CNVA
Best spectacle-corrected near visual acuity (CNVA)
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Apr 2020
- Study start14 Aug 2020
- Primary completion31 Dec 2020
- Study completion31 Dec 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dry Age-related Macular DegenerationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 17 participants (actual)
Sponsor and investigators
- Lead sponsor
- Optimal Acuity Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Bochner Eye Institute
- Responsible party
- Sponsor
- Investigators
- Michael Berry, PhD, Principal investigator, Optimal Acuity Corporation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04349254
- Sponsor's protocol ID
- Retro1
- Status last verified
- Feb 2021
- First submitted
- 14 Apr 2020
- Last updated
- 24 Feb 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observational Study of Vision Improvement in Late Stage Dry AMD Patients by a Low Vision Aid Device
- ClinicalTrials.gov ID
- NCT04349254
- Acronym / sponsor ID
- Retro1
- Conditions
- Dry Age-related Macular Degeneration
- Keywords
- Dry AMD
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 17 participants (actual)
- Lead sponsor
- Optimal Acuity CorporationIndustry (pharma, biotech, devices)
- Collaborators
- Bochner Eye Institute
- Study start
- 14 Aug 2020 (actual)
- Primary completion
- 31 Dec 2020 (actual)
- Study completion
- 31 Dec 2020 (actual)
- First posted
- 16 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to assess the vision improvement achieved by patients with late stage dry age-related macular degeneration who received corneal treatments by a low vision aid device.
Detailed description
The purpose of this study is to assess the vision improvement achieved by patients with late stage dry age-related macular degeneration who received corneal treatments by a low vision aid device. Patient records for patients with at least 12 months follow-up will be analyzed to determine measures of vision improvement including best spectacle-corrected distance and near visual acuity. Analyses will include descriptive statistics and correlation between outcomes and baseline characteristics.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 50 to 100 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with vision impairment due to late stage dry age-related macular degeneration.
Key inclusion criteria (7 listed)
- - Male or female
- - Any race
- - Patient is at least 50 years old
- - Patient has diagnosed late stage dry age-related macular degeneration in one or both eyes.
- - Treated eyes were pseudophakic at the time of treatment.
Key exclusion criteria (4 listed)
- - Corneal disease or disorder in either eye.
- - Increased intraocular pressure (above 20 mm Hg), glaucoma or history of glaucoma.
- - Presence or history of any other condition or finding that, in the opinion of the investigator, makes the patient unsuitable for retrospective observational study.
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Corneal treatment by a low vision aid deviceNear infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The change of modulus produces a change of corneal stiffness and shape that modifies the distribution of light onto the retina. Light rays are redirected from dysfunctional areas of the retina that have been damaged by age-related macular degeneration (AMD) to functional areas of the retina, thereby improving patient vision. | Device | – |
Primary outcome
CDVA
Time frame: 12 months
Best spectacle-corrected distance visual acuity (CDVA)
1 secondary outcome
CNVA
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Feb 2021.
- Individual participant dataSharing planned: No
Related trials for Dry Age-related Macular Degeneration
RecruitingPhase 1/2
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
Dry Age-Related Macular Degeneration, Geographic Atrophy
Not yet recruiting
Safety and Clinical Performance of the LENTIS® MAX LS-313 MF80 Compared With the Monofocal L-313 in Cataract Patients With Late Age-Related Macular Degeneration: A Multicenter Comparative Clinical Investigation.
Cataract, AMD - Age-Related Macular Degeneration
Not yet recruiting
MacuMira Microcurrent Stimulation for Dark Adaptation in Dry Age-Related Macular Degeneration
Age-Related Macular Degeneration (AMD)
Active, not recruitingPhase 1/2
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
Geographic Atrophy
Active, not recruitingPhase 1/2
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
Age-Related Macular Degeneration
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael Berry, PhD principal investigator
Optimal Acuity Corporation
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Dry Age-related Macular Degeneration, run by Optimal Acuity Corporation at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
CDVA (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2021.